Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Septerna, Inc. (NASDAQ:SEPN) has received an average rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $43.1250.

SEPN has been the topic of several recent analyst reports. Truist Financial lifted their price objective on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. lifted their price objective on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Finally, Stifel Nicolaus initiated coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price objective on the stock.

Septerna Price Performance

Shares of SEPN stock opened at $31.15 on Monday. The stock has a 50-day moving average price of $26.15 and a 200 day moving average price of $26.50. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -38.46 and a beta of 2.39. Septerna has a 12 month low of $9.85 and a 12 month high of $32.63.

Septerna (NASDAQ:SEPN) last issued its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The firm had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Sell-side analysts predict that Septerna will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Samira Shaikhly sold 5,935 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $28.93, for a total value of $171,699.55. Following the transaction, the insider directly owned 793 shares in the company, valued at $22,941.49. This trade represents a 88.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,733 shares of company stock worth $623,707 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its holdings in shares of Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. Vanguard Group Inc. boosted its stake in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after purchasing an additional 104,394 shares during the period. Avoro Capital Advisors LLC boosted its stake in Septerna by 8.1% in the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after purchasing an additional 100,000 shares during the period. ADAR1 Capital Management LLC boosted its stake in Septerna by 38.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after purchasing an additional 329,264 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in Septerna in the 1st quarter valued at $21,334,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.